We also observed increased expression of the anti-apoptotic molecule BCL-xL (BCL2L1) in venetoclax-treated animals, consistent with findings from CLL patients after venetoclax therapy. Here, BCL2L1 is linked to B-cell chronic lymphocytic leukemia.